Replies to post #150616 on Biotech Values

[DewDiligence]

Thanks for the clarification. Obviously that should result in lesser late relapse - but the interesting question is how much less even the lesser regimen got >90% EOT response (if I remember correctly) and yet had meaningful late relapse.

Two points:

1. The 99% (treatment-naïve) and 93% (null-responder) figures reported in ABT’s abstract today were SVR12, not EoT. (However, the SVR12 numbers were not on a strict ITT basis because data were not available for all patients at the time the abstract was submitted.)

2. The PILOT study included only treatment-naive patients, so the AVIATOR study’s 93% SVR12 in null responders does not have a comparator from PILOT.